Manganese superoxide dismutase-plasmid liposomes (MnSOD-PL) confer organ specific in vivo ionizing irradiation protection. To prepare for potential intravenous clinical trials of systemic MnSOD-PL for radioprotection in humans, plasmid and bacterial sequences were removed and a new mini circle construct was tested. Mini circle-MnSOD was purified and then co-transfected into 32D cl 3 murine IL-3 dependent hematopoietic progenitor cells along with another plasmid containing the neo gene. Cells were selected in G418 (50 µg/ml) and cloned by limiting dilution. 
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INTRODUCTION
Ionizing irradiation induces cellular, tissue, and organ toxicity by mechanisms which include induction of radical oxygen species (ROS) (Spitz et al., 2004; Mitchell and Krishna 2002; Hahn et al., 2000; Weiss and Landauer, 2000; Epperly et al., 2004) . Antioxidant defenses include the bioavailability of ROS-neutralizing enzymes which modulate ionizing irradiationinduced damage (Spitz et al., 204) In particular, three forms of superoxide dismutase, two extracellular copper/zinc metalloenzymes, and one mitochondrial targeted manganese metalloenzyme, dismutate superoxide to hydrogen peroxide which is then further acted upon by enzymes including catalase and glutathione peroxidase to form water . One approach toward increasing cellular and tissue defenses against ionizing irradiation has been through utilization of a gene therapy technique to overexpress mitochondrial manganese superoxide dismutase prior to irradiation exposure or intermittently during fractionated irradiation (Greenberger et al., , 2004 (Greenberger et al., , 2007 Epperly et al., 2001 Carpenter et al., 2005) .
For therapeutic application of a gene therapy technique in radiation protection, transgene expression during the time of irradiation exposure is desirable, and should be followed by clearing of the transgene cDNA, as well as RNA and protein from the system (Greenberger et al., , 2004 (Greenberger et al., , 2007 Epperly et al., 2000; . Plasmid liposomes have offered an attractive vehicle by which to achieve such transient overexpression, and this technique of antioxidant gene 05/23/2008 4 Systemic, intravenous administration of plasmid liposomes has been reported to be associated with an inflammatory response which may be attributable to CPG sequences within the bacterial plasmid backbone of the construct (Sellens et al., 2005) . Recently, a novel approach has been utilized to create mini circle-plasmid constructs which eliminates the bacterial CPG sequences (Chen et al., 2005) . In the present studies, we sought to determine whether mini circle-plasmid liposomes containing the human MnSOD transgene could be utilized for in vitro and in vivo radioprotection and whether this construct eliminated the inflammatory response through removal of bacterial CPG sequences while retaining therapeutic transfer and transient expression of MnSOD biochemical activity.
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MATERIALS AND METHODS
Construction of Mini Circle-MnSOD-Plasmid: The minicircle MnSOD vector was based on the p2ØC31, minicircle parent plasmid DNA vector, constructed by Dr. Zhi-Ying Chen (Chen et. al. 2005) . The human MnSOD transgene was amplified by polymerase chain reaction (PCR) from the plasmid pNGVL3-MnSOD. The 1482 bp human MnSOD gene expression cassette, including a human cytomegalovirus (CMV) promoter, human MnSOD gene and a poly A tail was inserted into the site between Spe I and Xho I in the p2ØC31 plasmid, resulting in the plasmid p2ØC31.MnSOD (Figure 1) . A control minicircle construct containing the DS-red transgene was prepared using the same procedures.
Minicircle Production: The protocol for minicircle plasmid isolation as previously described by Chen et al (Chen et al., 2005) was used to produce minicircle MnSOD. Plasmids p2ØC31.MnSOD or p2ØC31.DS-red were transformed to Escherichia coli Top 10 (Chen et al., 2005) , and a single colony was grown overnight in fresh LB broth at 37 o C, then pelleted in a centrifuge (Beckman Coulter Avanti J-20 XP) at 20°C, 3000 rpm for 20 min. The pellet was resuspended at 4:1 (v/v) in fresh LB broth containing 1% L-arabinose. The bacteria were incubated at 32°C with shaking at 250 rpm for 2 hours at which time an additional one and half volumes of fresh LB broth (pH 8.0, containing 1% L-arabinose) was added and the incubation continued at the increased temperature of 37 o C for 2 hr. The minicircle DNA was prepared following the instruction in plasmid purification kits from Qiagen. Agarose gel electrophoresis was used for minicircle DNA purification to obtain 100% pure minicircle DNA.
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sequenced using an ABI PRISIM 3700 DNA sequencer to confirm that the minicircle contained the MnSOD expression cassette.
Cell Lines and Cell Culture: The 32D cl 3 mouse hematopoietic progenitor cell line, dependent for growth upon Interleukin 3, has been described previously (Epperly et al., 2002 . 32D cl 3 cells were passaged in fresh RMPI 1640 medium containing 10% FBS, 1% Lglutamine, 1% penicillin/streptomycin, and 15% WEHI-3 conditioned medium as a source of IL-3. Twenty-four hours later, 1 X 10 7 32D cl 3 cells were washed twice in PBS and resuspended in 0.25 ml of PBS. For each electroporation 5 microgram (1 µg/µl) p2ØC31.MnSOD or p2ØC31.DS-red plus 0.5 µg of pSV2-neo were added to the 32D cl 3 cells and transferred to an electroporation cuvette (BioRad, Cat. No. 165-2088) . A BioRad Gene Pulser II set to 280 V, and 950 µF was used to electroporate the cells. The cells were then placed on ice for 20 min and transferred to a flask containing pre-warmed medium. Two days after electroporation, transfected cells were selected by addition of 500 mg/µl of G418 according to published methods (Epperly et al., 2002) . A clonal line was selected by limiting dilution and expanded as previously described (Epperly et al., 2002) . Subclones expressing the MnSOD or DS-red transgenes were identified by RT-PCR using primers specific for MnSOD or DS-red as previously described (Epperly et al., 2002) . A subclone of 32D cl 3, overexpressing the human MnSOD transgene (2C6) has been reported previously (Epperly et al., 2002 . Both cell lines were grown in WEHI-3 cell conditioned medium as a source of IL-3, in a high humidity incubator, in RMPI 1640 medium supplemented with 10% fetal bovine serum as described (Epperly et al., 2002) . (Epperly et al., 2002 .
Biochemical Analysis of MnSOD Activity: The NBT reduction assay for MnSOD biochemical activity was carried out according to published methods (Epperly et al., 2002) . shielding of the abdomen and head using a Varian Linear Accelerator at 300 monitor units/min according to published methods . In other experiments total body irradiation was delivered to a dose of 9.75 Gy at a rate of 0.8 Gy/min using a Shepherd Mark IV cesium irradiator according to published methods . All animal protocols were approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Esophageal Administration of Radioprotective Transgenes: C57BL/6J female mice received intra-oral administration of 100 µl of water followed by full length pNGVL3-MnSOD, blank pNGVL3 plasmid, MC-MnSOD, or control minicircle-plasmid by injection of 100 µl volumes of liposomes containing 100 µg of pNGVL3-MnSOD or blank pNGVL3 blank plasmid DNA or 50 µg plasmid of MC-MnSOD or MC-DS-red plasmid DNA according to published methods (Epperly et al., 2001 ). The plasmid DNA was mixed with 28 µl of lipofectin (Invitrogen, Carlsbad, CA) and allowed to complex at room temperature for 10 min before administration.
Mice were not anesthetized, and were allowed to swallow plasmid liposome preparations.
Esophagus irradiation was carried out by anesthetizing the mice with Nembutal and irradiation of the esophagus to 31 Gy using a linear accelerator according to previously published procedures (Stickle et al., 1999) . Mice were held and followed for evidence of esophageal toxicity including weight loss, and dehydration. Animals were sacrificed by euthanasia when weight loss was greater than 20%, according to institutional IACUC protocols.
Total Body Irradiation Protection: Mice received intravenous administration of 100 µl of liposomes containing either 100 µg pNGVL3-MnSOD or pNGVL3 blank plasmid DNA or 50 µg plasmid of MC-MnSOD by tail vein injection, 24 hours prior to irradiation. The DNA was complexed with lipofectin as described above. The LD 50/30 dose of irradiation of 9.75 Gy total body dose was administered 24 hours after gene therapy using a Shepherd Mark IV cesium irradiator according to published methods . Mice were followed for development of hematological distress and were sacrificed when moribund or demonstrating greater than 20% weight loss according to institutional IACUC protocols. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
RESULTS
Production of minicircle MnSOD plasmid: Minicircle MnSOD or DS-red plasmids were
constructed by inserting the MnSOD expression cassette containing the human MnSOD transgene, CMV promoter, and poly A tail into the p2ØC31 plasmid ( Figure 1A ). The minicircle MnSOD plasmid was isolated and the gene sequence was obtained indicating that the minicircle contained 54 bp from the p2ØC31 plasmid, the CMV promoter, the human MnSOD transgene, and the poly A tail ( Figure 1B) . A control plasmid containing the CMV promoter, DS-red transgene and poly A tail was also constructed and sequenced ( Figure 1B ).
Transfection of 32D cl 3 cells: Cells from 32D cl 3 were co-transfected with either the MnSOD minicircle plasmid or DS-red minicircle plasmid and pSV2-neo plasmid by electroporation and selected for cells exhibiting neo-resistance. The cells were cloned by limiting dilution and RT-PCR was performed using primers specific for MnSOD or DS-red transgenes to identify clones expressing either the MnSOD transgene or DS-red transgene.
Isolation of the MnSOD minicircle plasmid yielded 0.25 to 0.5 mg of 1532 bp minicircle DNA from 1.0 liter of overnight bacterial growth. The DNA purity is about 70 to 80% compared to the 95% reported by Chen (Chen et al., 2005) .
MnSOD Biochemical Activity: The MnSOD biochemical activity was determined in 32D cl 3, 2C6 or 32D-MC-SOD cells. Cells were lyzed by repeated freeze-thaw cycles with protein concentrations measured. Using an assay where the reaction between xanthine and xanthine oxide liberates superoxide which then reduces NBT resulting in an increase in color change (Epperly et al., 2002) . The presence of SOD removes the superoxide preventing the color change This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
µl of lipofectant and incubated for 10 minutes at room temperature. The plasmid/liposome complexes were each administered by plastic syringe to the top of the esophagus of nonanesthetized C57BL/6NHsd female mice (15 per group) and mice were allowed to swallow the complexes as published (Stickle et al., 1999) . The PL treated mice as well as untreated control mice were then irradiated 24 hr later to 31 Gy to the esophagus and the mice followed for the development of esophagitis (Figure 4 ). Mice swallowing either MC-SOD-PL or MnSOD-PL had improved survival following irradiation compared to the irradiated control mice (p = 0.0003 or < 0.0001, respectively). Mice given pNGVL3-PL had some detectable increased survival compared to the control irradiated mice (p = 0.0012), but there was further improved survival in those given MnSOD-PL. In contrast, there was no significant difference in survival between control irradiated mice and mice injected with control minicircle DS-red-PL. The mice given MC-MnSOD-PL had a significantly increased survival compared to control minicircle DS-red-PL treated mice (p = 0.0391).
In Vivo Radiation Protection Against Total Body Irradiation: To demonstrate that overexpression of MnSOD in a pNGVL3 or mini-circle plasmid could be safely administered systemically, C57BL/6NHsd female mice (15 mice per group) were injected intravenously via the tail vein with MnSOD-PL, MC-MnSOD-PL, or pNGVL3 plasmid, and irradiated 24 hr later along with control mice to 9.75 Gy whole body irradiation. The mice were followed for signs of hematologic stress at which time they were sacrificed ( Figure 5 ). MC-MnSOD-PL as well as full length MnSOD-PL provided significant protection from 9.75 Gy T.B.I. (p<0.0001, p = 0.0340, respectively). This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
DISCUSSION
The development of systemic protection agents against total body ionizing irradiation is a focus of great scientific interest (Stone et al., 2004) . Normal tissue specific radioprotection is highly desirable in the development of new chemoradiotherapy programs for clinical cancer patient management . Furthermore, normal tissue specific radioprotection in the total body irradiated patient has been the subject of particular interest particularly since solid tumors have been demonstrated to have a different redox balance compared to normal tissues (Spitz et al., 2004) . Organ specific systemic radioprotector agents have included strategies to neutralize inflammatory cytokines using small molecule antioxidants, by targeting the apoptotic cellular mechanism of death by administration of agents that upregulate anti-apoptotic proteins, or neutralize pro-apoptotic proteins (Greenberger and Epperly, 2007) . Each of these strategies has provided some success. However, management of side effects, and incomplete systemic delivery have been complicating factors.
One approach toward radiation protection has focused on the cellular and tissue redox balance mechanisms and their alteration by ionizing irradiation Greenberger et al., 2003) . Antioxidant stores within cells include glutathione, and other free radical scavenging antioxidants. Prominent in this cellular arsenal are the antioxidant enzymes including superoxide dismutases (Spitz et al., 2004; Mitchell et al., 2002; Hahn et al., 2000) .
Two forms of copper/zinc metalloenzyme, one intracellular, and another extracellular are involved in systemic protection against agents that induce oxidative stress including tissue inflammation induced by ionizing irradiation (Spitz et al., 2004) . Manganese superoxide dismutase, the third form of SOD, targets the mitochondria by a 22 amino acid targeting sequence . Specific localization of SOD to the mitochondria appears This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
necessary for radiation protection of cells in vitro and tissues in vivo since removal of the mitochondrial localization sequence produces MnSOD with cytoplasmic expression and little radioprotective capacity, while attaching this same mitochondrial localization signal to copper/zinc SOD results in a mitochondrial targeted and radioprotective copper/zinc metalloenzyme .
Administration of MnSOD protein to cells in culture or tissues in vivo has not shown significant radioprotective capacity, in part because of difficulty in achieving high enough levels of protein at the mitochondrial membrane where critical antioxidant function is required (Epperly et al., 2001) . In contrast, administration of transgene cDNA for MnSOD results in transport to the mitochondria at high efficiency of mitochondrial targeted protein and has been shown to confer radioprotection to cells in vitro and tissues in vivo (Epperly et al., 2002; Carpenter et al., 2005; Stickle et al., 1999) .
For systemic radiation protection, intravenous administration of plasmid liposomes has been shown to have a worrisome toxicity of inflammation induction (Sellens et al., 2005) and this has been attributable to CPG sequences in the bacterial backbone of the plasmid (Sellens et al., 2005 ). An important strategy toward eliminating the negative side effects of plasmid liposome gene therapy has recently been reported by demonstration of a technique by which to construct a mini circle-plasmid devoid of bacterial CPG sequences (Chen et al., 2005) .
In the present studies, we utilized this published technique of construction of mini circleplasmid to produce a MnSOD-mini circle demonstrating its effectiveness in transferring the human MnSOD transgene mediated biochemical activity to mouse, hematopoietic progenitor cells in vitro, and to the esophagus of mice in vivo. Furthermore, intravenous administration of This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
mini circle-MnSOD was associated with protection from the LD 50/30 total body irradiation dose of 9.75 Gy.
Previous studies demonstrated some radioprotective capacity of empty full length plasmid, PNVL3 or PRK5 (Epperly et al., 1999) . This protection was associated with an inflammatory response that could be detected in tissues as an increase in mRNA for TNF , IL-1, and TGF (Epperly et al., 2001) . While a non-specific inflammatory response may be radioprotective in some organ specific settings, there is concern that systemic introduction of a gene therapy vector that itself is inflammatory might be deleterious in a setting of victims of an irradiation accident or willful irradiation terrorism event, wherein the ionizing irradiation itself and combined injury (heat, physical trauma) would be inflammatory. The present MC-MnSOD gene therapy vehicle should eliminate inflammatory side effects of the vector but maintain sufficient radioprotective capacity to allow its utilization in intravenous administration in larger mammalian species including humans.
Preparation of MC-MnSOD constructs was not a trivial process. The techniques for bacterial growth, centrifugation, purification, and extraction of mini circle-plasmid were complex. Furthermore, previous studies demonstrated yield of mini circle as high as 96% of total recovered plasmid liposome (Chen et al., 2005) , while in the present studies yield rates as low as 68% were noted. These differences were not attributable to obvious changes in laboratory technique, bacterial expression system, centrifugation technique, or extraction methods. It is possible that the MnSOD transgene or other antioxidant transgenes yet to be tested may, as part of the insertion and recombination process, result in a lower yield of mini circle construct.
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